http://orcid.org/0000-0002-0340-0443
Figures
Abstract
Background
In Ethiopia, Multi-drug resistant Tuberculosis (MDR-TB) is one of the major public health problems that need great attention. Time to sputum culture conversion is often used as an early predictive value for the final treatment outcome. Although guidelines for MDR-TB are frequently designed, medication freely provided, and centers for treatment duly expanded, studies on time to sputum culture conversion have been very limited in Ethiopia. This study was aimed at determining the time to sputum culture conversion and the determinants among MDR-TB patients at public Hospitals of the Amhara Regional State.
Methods
A retrospective follow up study was conducted between September 2010 and December 2016. Three hundred ninety two MDR-TB patients were included in the study. Parametric frailty models were fitted and Cox Snell residual was used for goodness of fit, which the Akaike’s information criteria was used for model selection. Adjusted hazard ratio (AHR) with a 95% confidence interval (CI) was reported to show the strength of association.
Result
Out of the 392 participants, sputum culture changed for 340(86.7%) during the follow up period. The median culture conversion time in this study was 65 (60–70 days). Alcohol drinking (AHR = 3.79, 95%CI = 1.65–8.68), sputum smear grading +2 (AHR = 0.39, 95%CI 0.19–0.79), smear grading +3 (AHR = 0.30, CI = 0.14–064), cavitations (AHR = 0.36, 95%CI = 0.19–0.68), and consolidation (AHR = 0.29, CI = 0.13–0.69) were the determinants of time to sputum culture conversion.
Conclusion
In this study, time to sputum culture was rapid as compared to 4 months WHO recommendation. Alcohol drinking, sputum smear grading, cavitations and consolidations were found to be the determinants of time to sputum culture conversion. Therefore, providing a special attention to patients who had baseline radiological finding is recommended, high bacillary load and patients with a history of alcohol intake at baseline should be given priority.
Citation: Yihunie Akalu T, Muchie KF, Alemu Gelaye K (2018) Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: A multicenter retrospective follow up study. PLoS ONE 13(6): e0199320. https://doi.org/10.1371/journal.pone.0199320
Editor: Ulrike Gertrud Munderloh, University of Minnesota, UNITED STATES
Received: October 5, 2017; Accepted: May 9, 2018; Published: June 21, 2018
Copyright: © 2018 Yihunie Akalu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data contains potentially identifying characteristics as well as sensitive patient information (e.g. HIV status). Therefore, please send all data requests to the Director of Institute of Public Health (Dr Gashew Andargie at gashawab@gmail.com), or Postgraduate committee of Institute of Public Health at University of Gondar (Mr. Yohannis Ayana at yohaneshabitu@gmail.com).
Funding: This work was supported financially by University of Gondar. However, the University had no role in study design, data collections and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: AFB, Acid fast bacilli; AIC, Akaike Information Criteria; BIC, Bayesian information Criteria; BMI, Body Mass Index; CHR, Chest X-RAY; CHR, Crude Hazard Ratio; CS, Cyclo Serine; DM, Diabetic Mellitus; DOTS, Direct Observed Therapy Short Course; ETHO, Ethionamid; HGB, Hemoglobin; HIV, Human Immune- Deficiency Virus; HPF, High Power Field; HR, Hazard Ratio; HTN, Hypertension; Kg/m2, Kilogram Per Meter Square; LFX, Levofloxacin; LPA, Line Prove Assay; MDR, Multi Drug Resistant; PAS, Paramino Salicylic Acid; PI, Principal Investigator; PRO, Prothionamide; TB, Tuberculosis; TIC, Treatment Initiating Center; UOGRH, University Of Gondar Referral Hospital; WHO, World Health Organization; XDR, Extensive Drug Resistant; Z, Pyrazinamide
Introduction
Tuberculosis (TB) which kills approximately 2 million globally every year has been the second leading cause of morbidity next to the human immune deficiency virus (HIV) [1, 2]. The multidrug resistant (MDR) TB is an increasing global problem [3]. Proper treatment and enhanced case detection is needed to ensure good success rate and halt the emergency of MDR or extensively drug resistant (XDR) TB, as the risk is high among previously treated patients [4]. The treatment of MDR-TB takes 2 years (18–24 months), and monthly sputum culture is considered as a remarkable indicator of treatment effectiveness, especially during the intensive phase of treatment [5]. Knowing the time to sputum culture conversion is often used as an early predictive value for the final treatment outcome, especially in MDR-TB patients [2], and a delayed after four-month conversion was considered as a precondition for suspecting MDR-TB treatment failure [2].
According to 2017 global report, there were an estimated 600,000 (range, 540 000–660 000) new cases of MDR/Rifampin resistance (RR)-TB were reported. Of this, only 22% were officially diagnosed and 54% cure rate [6].
About 88% of the anticipated MDR-TB cases were found in Brazil, China, India, the Russian Federation, and South Africa [7], while its impact worsened in Asia and Africa [8]. According to the 2015 global report, 28% of MDR-TB patients were found in the African region [2], Ethiopia ranked 15th among the 27 high MDR-TB burden countries with more than 5000 estimated MDR-TB patients each year. The prevalence is 2.8% in newly diagnosed patients and 21% in patients under re-treatment [9].
The most common factors that affect time to sputum culture conversion are: MDR-TB category, HIV co-infection, presence of radiological findings, presence of chronic diseases, number of resistant drugs at initiation, number of active drugs taken, and therapeutic delay of greater than one month [10–13].
Delaying sputum culture conversion resulted in economic wastage by prolonging the duration of treatment, poor treatment adherence and consequently failing treatment. It is also associated with higher case fatality rates (50–80%) as a result of drug toxicity, leading to the emergence of XDR-TB [13]. Despite the provision of free treatment, monthly culture monitoring, and expansion of services, studies on time to sputum culture conversion in our country including the study area is very limited. Therefore, this study is aimed to determine the time to sputum culture conversion and its determinants among MDR-TB patients.
Materials and methods
Study design and setting
An institution based retrospective follow up study was conducted from September 2010 to December 2016 among MDR-TB patients in three at the nine public hospitals of Amhara Regional State. Namely: University of Gondar Referral Hospital (UOGRH), Borumeda Hospital, and Debre-Markos Referral Hospital. These hospitals were among the nine hospitals in the region, at which about 80% of the patients received treatment.
University of Gondar Referral Hospital, which is located in North Gondar Administrative Zone, the Amhara Regional State, started MDR-TB treatment as a pilot program with the Global Health Commute (GHC) to treat patients as a national response to the emerging threat of drug resistant TB in September 2010. Currently, Gondar town has a referral hospital, eight health centers, and fourteen health posts owned by the government. There also are one general Hospital, thirteen specialties, fifteen medium, and ten primary clinics run by private sector. The University of Gondar Referral Hospital is a teaching hospital which serves more than five million people of North Gondar and neighboring zones, as well as the Tigray Region. The second setting is Debre-Markos Referral Hospital, which is located in Debre-Markos town (capital of East Gojjam). It is 297 km from Addis Ababa and 264 km from Bahirdar, the capital of the region. The MDR-TB center established recently was giving service to 50 patients. The third setting is Borumeda Hospital located 10 km from Dessie, the capital of South Wello and 441 km from Addis Ababa. The center was established in 2013 and was serving 131 MDR-TB patients.
Population and sample
Gondar, Debre-Markos and Borumeda referral hospitals were selected out of the nine hospitals in the region. All drug resistant TB patients who were culture positive at the start of treatment at least for two months and had follow up were included in the study. Patients who had incomplete data on the outcome variables were excluded. Culture positive MDR-TB patients followed for less than two months and were culture negative at baseline were excluded. A total of 392 MDR-TB patients which fulfilled the inclusion criteria took part in study.
Data collection procedures and variables
Time to sputum culture conversion was the response variable, where as socio-demographic characteristics (sex, age, residence, educational status, marital status), behavioral factors (smoking, alcohol drinking) and clinical characteristics(HIV co-infection, MDR category, MDR treatment regimen, type of resistance, presence of chronic diseases, clinical complications, radiological findings, therapeutic delays> 1 month, base line Body Mass Index (BMI), smear grading and functional status) were the explanatory variables.
Time to sputum culture conversion- was defined as the time from initiation of treatment of MDR-TB for a patient who had two negative consecutive cultures taken at least 30 days apart after initiation of treatment, censored was defined as when the outcome of interest has not been observed for an individual. This includes treatment stopped while culture was positive, died before conversion, transferred out before conversion, and study time completion before culture conversion. Therapeutic delay was defined as confirmed MDR-TB patient who started treatment after one month of MDR-TB diagnosis, previously not treated for TB was defined as a patient who had no prior anti-TB treatment or taken anti TB for less than one month. Previously treated case was defined as a patient who was treated for TB for one month or more, a patient who had under <18.5 kg/m2 body mass index was classified as low BMI, where as a patient who had ≥18.5kg/m2 body mass index was classified as normal BMI. Acid Fast Bacilli (AFB)Sputum smear microscopy was performed at baseline and on monthly follow-up using Ziehl- Nielsen staining. Results are reported based on the number of AFB: negative (no AFB/ 100 high-power fields [HPF]), scanty (1–9 AFB/100 HPF), 1+ (10–99 AFB/100 HPF), 2+ (1–9 AFB/HPF), and 3+ (>9 AFB/HPF).
Data management and analysis
Prior to data collection, records (both baseline and follow up) were reviewed and identified by their medical registration/card numbers. Trained data collectors (nurse and health officer) reviewed and extracted data from patient charts and registries, using a semi structured check list. The filled formats were checked for completeness by the principal investigator and three supervisors. The data were entered in to EPI info version 7 and exported to Stata version 14 statistical software for further analysis.
Descriptive summary statistics, like the median time of culture conversion and Kaplan Meier curve estimations were computed. Proportional hazard assumption (PHA) was checked using graphs and Schoenfeld residuals tests. The Cox regression model for bivariable and multi variable analyses was done. Model comparison was carried out based on Akaike Information Criterion (AIC). Then, parametric frailty models were fitted and compared to identify the potential determinants. Goodness of fit was checked by Cox Snell residual test. Final results were taken as significant at 5% level of significance. The Adjusted Hazard Ratio (AHR) with its respective 95% Confidence Interval (CI) was reported to show the strength of association.
Ethical issues
The ethics committee of Institute of Public Health, College of Medicine and Health Sciences, University of Gondar approved this study. Similarly, informed consent was not taken from the study participants directly as it is entirely secondary and no access to meet the study subjects. However, the committee gave accreditation for the approval and permission letter was obtained from Amhara regional state. Then permission was also requested from each hospitals and informed consent also waived by each respective hospitals for their patients. All data were de-identified prior to access by authors. The check list was kept securely in locked cabinets and the data base was password protected.
Results
Baseline socio-demographic characteristics
About 428 pulmonary MDR-TB patients were reviewed. Among these, 36 (8.4%) were excluded from the study because of baseline negative culture and contaminated results. Thus, a total of 392 (91.6%) study units were included in the analysis. The majority of the patients were attended at the University of Gondar Referral Hospital; 242(61.7%) were followed at Borumeda hospital,113(28.8%), and the remaining at Debre-Markos Referral Hospital.
The median age of the MDR-TB patients at initiation of treatment was 29.5 years IQR (20–40 years). One-third of the participants, 127 (32.4%), were under 25years of age. More than half of the respondents, 228(58.2%), were males and about half of them, 200(51%), were urban dwellers. About 168(42.9%) were private workers, and 314 (80.1%) were Orthodox Christian’s. Around 40% of the MDR-TB patients were not formally educated, and 164 (41.8%) were married (Table 1).
Baseline clinical status
Among the 392 MDR-TB patients, 9.9% had chronic disease. Of these, 12 (3.1%) had diabetic mellitus (DM) and 4 (1%) hypertension (HTN). About one fourth (25.8%) of the MDR-TB patients had HIV co-infection, the majority 272(69.4%) were ambulatory, and 376 (95.9%) hospitalized at initiation of treatment. About 11 (2.8%) of the participants had previous MDR-TB treatment, and nearly half 199(50.8%)were mono resistant (Rifampin resistant). Regarding the x-ray finding, 107 (27.3%) of the MDR-TB patients had infiltration and 160(40.82%) cavitations. About 286 (73.0%) of the participants had low BMI (<18.5kg/m2) and 7 (1.8%) had treatment modification. Of 7 MDR-TB patients, 5 were MDR-TB treatment failure suspect, one patient was XDR-TB confirmed, and one was a life threatening drug side effect. About350 (89.3%) were previously treated for TB (Table 2).
Diagnosis method and treatment outcome
Next to cough, fever, which affected 366 (93.4%) was the most common presentation of the patients, followed by 365 (93.1%) who lost weight. Of 392 MDR-TB patients, 136 (34.7%) had shortness of breath and 285 (72%) chest pain. About 319 (81.4%) participants had history of fatigability and 305 (77.8%) history of poor appetite. The methods of diagnosis employed for 177 (45.2%), 139 (35.4%), 64 (16.3%), and 12 (3.1%) of the MDR-TB patients were Mycobacterium Tuberculosis (MTB) /gene expert, Line Probe Assay (LPA), culture/Drug susceptibility test (DST), and clinical, respectively. Of the 392 MDR-TB patients, 52 (13.3%) were censored and 340 (86.7%) converted their culture. The overall cure rate of MDR-TB patients was 216(55.1%) and 12 (3.1%) completed their treatments (Fig 1).
Time to sputum culture conversion
The participants were followed for a total of 1000.6 person months (83.4 person years) observation. The median follow up period was 65 days (IQR: 61–70). The cumulative probability of survival on initial conversion was 0.89 at the end of one month, 0.56 at the end of two months, and 0.19 at the end of four months (Fig 2).
Differences in all variables at baseline between strata were determined using the log rank (χ2) test, and the equality of hazard was assessed for the different explanatory variables. According to the test results, the presence of infiltration p-value = 0.00, cavitations p-value = 0.00, consolidation p-value = 0.01, Fibrotic change p-value = 0.00, functional status p-value = 0.03, sputum smear grading p-value = 0.00 and resistance type p-value = 0.00associated with initial culture conversion time at 5% level of significance.
The Schoenfeld global test of the functional status satisfies the PHA (P-value = 0.294). The mean survival time, on culture conversion for patients who were bedridden had a median conversion time of 87 days, whereas ambulatory and working patients had median conversion times of 63 and 56, respectively, and the difference was significant (p-value = 0.0318) (Fig 3).
The median culture conversion times at Gondar, Borumeda, and Debre-Markos hospitals were 65 CI (61–76), 63 (53–80), and 62 (42–76) days, respectively (Fig 4).
Determinants of time to sputum culture conversion
Similarly, the proportional hazard assumption was checked by the Schoenfeld residual global test, and p-value showed 0.68. So, proportional hazard assumption was met. Based on Akaike Information Criterion (AIC), the univariate frailty with Weibull distribution and gamma frailty (AIC = 396.82) model was more efficient than Cox-proportional hazard (AIC = 1859.41), parametric exponential model (AIC = 545.05), and other frailty models (Table 3). Thus, the inclusion of shared frailty term showed no statistically significant variance and indicated that there was no any shared heterogeneity or shared unobserved variability among hospitals. But there was a statistically significant heterogeneity among individuals (variance = 1.56)(Table 4). Goodness of fit for the fitted model was also performed using the Cox Snell residual test and showed that the model was adequate (Fig 5).
The finding from the bivariate analysis showed that alcohol drinking, type of resistance, baseline sputum smear grading, and cavitations at baseline, baseline infiltration, baseline consolidation, chronic fibrotic change at the baseline, and baseline functional status were significantly associated with culture conversion time. However, in the multi-variable analysis, alcohol drinking status, baseline sputum smear grading, baseline cavitations, and consolidation remained statistically significant predictors of time to sputum culture conversion. The rate of sputum culture conversion among who didn’t drink alcohol at baseline was 3.8 times as compared to alcohol drinkers(AHR = 3.8; 95%CI:1.7–8.7).
The rate of sputum culture conversion among MDR-TB patients whose baseline sputum smear grading was +2 decreased by 61%(AHR = 0.4;95%CI: 0.2, 0.8) as compared to MDR-TB patients whose baseline smear grading was +1. Similarly, the rate of culture conversion among MDR-TB patients whose baseline smear grading was +3 decreased by 70% (AHR = 0.3;95%CI 0.1, 0.6)) as compared with those baseline sputum smear was +1. Regarding the x-ray findings of MDR-TB patients who had cavitations at baseline decreased culture conversion time by 64% as compared to MDR-TB patients without cavitations(AHR = 0.36;95%CI:0.19,0.68)). Similarly, the rate of sputum culture conversion among MDR-TB patients who had consolidation at baseline decreased conversion time by 71% as compared to MDR-TB patients who had no consolidation (AHR = 0.29;95% CI:0.13,0.69)) (Table 4).
Discussion
In this study the median culture conversion time was 65 days. Previous baseline alcohol drinking status, baseline sputum smear grading, radiological findings, like cavity and consolidation were found to be the determinants of time to sputum culture conversion.
The median culture conversion time found in this study is in line with that of studies conducted in South Africa [14] and Georgia [15]. However, this finding showed a delayed conversion compared with a study conducted in Peru [16], which has a median conversion time of 59 days. In Peru [16]these DST results as well as other prior anti-TB drug exposures were taken into account when formulating the treatment regimen, but in our study DST was done when the start of treatment had some indication like previous history of MDR-TB, patients with HIV AIDS, failure with first line anti-TB, and contact with known MDR-TB treatment. In contrast, our study showed a rapid culture conversion time compared with multi centered studies conducted in five countries such as Peru, Latvia, Estonia, Russia, and the Philippines in which the median culture conversion time was 3 months (90days). Similarly, a study in Pakistan had a median conversion time of 191 days [13, 17]. This might be due to the way outcome variables were defined. In our study culture conversion time was explained by two consecutive negative culture results, whereas this was done by five consecutive negative culture results in the multicenter study. The second possible reason might be that a very small sample was used in the Pakistan study (N = 85). The third reason could be the fact that in present study MTB/Rif Xpert was used upon a positive sputum smear microscopy and the detection of Rifampicin resistance to place on standardized treatment regimen right from the beginning rather than waiting for DST results [17].
In MDR-TB patient’s, alcohol drinking resulted in delayed culture conversion time. This finding is in line with that of a multi centered study conducted in five countries like Peru, Estonia, the Philippines, Latvia, and Russia [13]. This might because a large number of MDR-TB patients who drink alcohol had cavitations in the multicenter study [13]. The second reason could be related to poor nutritional status, and the direct toxic effects of ethanol on the immune system or poorer adherence to anti-tuberculosis treatment [18, 19]. The third reason might be that alcoholism causes drug resistance by decreasing the immunity status [20].
In MDR-TB patients smear +2 and +3 resulted in delayed culture conversion time. This finding is in line with that of a study conducted in Latvia [21], Korea [22], and Indonesia [23]. Patients with high smear grading had high bacillary load. Having a high bacillary burden suggests a stronger infectivity and requires a longer isolation period and a more intensive treatment. Thus, it needs time to clear the bacilli if the bacillary load is high [22]. The second possible explanation could be that the presence of a high bacillary load is better associated with a reduction in bacterial killing and sterilizing activity of anti-TB drugs. It may be natural that patients with higher colony counts take longer time to convert sputum cultures [24].
Multi drug resistance TB patients who had baseline cavitations had delayed conversion time. The negative association between time to sputum culture conversion and lung cavitations in our study is in line with those of studies conducted in China [25] and Pakistan [26]. The possible reason might be the presence of lung cavitations decrease penetration and anti-bacterial activity of drugs [27]. In contrast to our finding, studies conducted in South Africa found no significant association between lung cavitations at baseline chest X-ray and culture conversion time [28]. The difference might be explained by a larger sample size and the four fold lower proportion of HIV co-infected patients used in our study [28].
The presence of baseline consolidation on chest radiography was associated with a longer time to initial sputum culture conversion as compared with MDR-TB patients who had no baseline consolidation. Consolidation occurs through the accumulation of inflammatory cellular exudates in the alveoli and the adjoining ducts. The liquid can be pulmonary edema, inflammatory exudates, pus, inhaled water, or blood (from bronchial tree or hemorrhage from a pulmonary artery). This minimizes the response to MDR-TB treatment and may delay the culture conversion time [29]. In contrast to this finding, a study conducted in South Africa revealed that there was no significant relationship between baseline consolidation and time to sputum culture conversion. This difference might be explained by the use of a small sample (n = 56) and a large number (88%) of HIV positive participants used in the study conducted in South Africa, showing these groups were immune-compromised, since, a radiological finding in immune compromised persons like HIV may not have sufficient lung finding [28].
Sputum culture conversion in MDR-TB patients is an important routine indicator in monitoring treatment outcome. Achieving more rapid sputum culture conversion can increase patients comfort by reducing the duration of injectable drug use and simplifying a patient’s therapy. In addition, from the public health perspective, reducing the time to sputum culture conversion is an important infection control measure because patients with MDR-TB and positive sputum cultures are infectious and may transmit the disease to other persons, family members, and health care providers [21]. The strength of this study is its incorporation of a multi-center site, and implementation of the frailty model estimation instead of a binary end point (logistic regression) for addressing the effect of unobserved heterogeneity, and handling interval censoring by using parametric survival analysis. Since the data were collected from secondary source, some important predictors like HGB, BCG scar, and income which had a significant association with time to sputum culture conversion in other studies were missed.
Conclusion
The time to culture conversion in our study is rapid as compared to WHO guidelines which recommend four months. Previous alcohol drinking, high baseline sputum smear grading, presence of cavitations and consolidation were found to delay time to sputum culture conversion.
Close follow-up and attention is important especially for those who were alcohol drinkers, have baseline cavitations, and consolidation. It is also useful to assess baseline sputum smear grading and provide great attention to those who have had a high bacillary load. Finally, we recommend that researchers conduct prospective follow up studies which include other independent variables (Anaemia, BCG scar, income).
Acknowledgments
We are thankful to data collectors, supervisors, radiographers, hospital administrators of the University of Gondar, Borumeda, and Debre-Markos hospitals.
References
- 1.
World Health Organization, Global tuberculosis report. 2013.
- 2. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. The Lancet Respiratory medicine. 2015;3(3):201–9. pmid:25726085
- 3. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. British medical bulletin. 2005(1).
- 4. Banu Rekha VV, Balasubramanian R, Swaminathan S, Ramachandran R, Rahman F, Sundaram V, et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. The Indian journal of medical research. 2007;126(5):452–8. pmid:18160750
- 5.
Organization WH. Guidelines for the programmatic management of drug-resistant tuberculosis. 2008.
- 6.
World Health Organization. Global Tuberclosis report. France: WHO; 2017.
- 7. Falzon D M F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? @ERSpublications. 2015;45:150–60.
- 8. Kakchapati S G B, Jha RK, Choonpradub aC. Treatment Outcome of Multidrug-Resistant Mycobacterium tuberculosis in Nepal. Asia-Pacific Journal of Public Health 2012;24(4):631–40. pmid:22652251
- 9. Biadglegne F S U, Rodloff aAC. Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care. aricjournal. 2014;3(31):2047–994.
- 10. Mulu W M D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. African health sciences. 2015;15(2).
- 11. Kanda R, Nagao T, Tho NV, Ogawa E, Murakami Y, Osawa M, et al. Factors Affecting Time to Sputum Culture Conversion in Adults with Pulmonary Tuberculosis: A Historical Cohort Study without Censored Cases. PloS one. 2015;10(11):e0142607. pmid:26558764
- 12. Lee J, Lee BJ, Yoon HI, Lee CT, Lee JH. Influence of previous tuberculosis treatment history on acid-fast bacilli smear and culture conversion. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2012;16(10):1344–8.
- 13. Kurbatova E, Gammino V, Bayona J, Becerra M, Danilovitz M, Falzon D, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2012;16(10):1335–43. pmid:23107633
- 14. Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, et al. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PloS one. 2011;6(1):e15841. pmid:21253585
- 15. Tierney DB, Franke MF, Becerra MC, Alcantara Viru FA, Bonilla CA, Sanchez E, et al. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PloS one. 2014;9(9):e108035. pmid:25238411
- 16. Tierney DB, Franke MF, Becerra MC, Alcántara Virú FA, Bonilla CA, Sánchez E, et al. Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment. Infection & Chemotherapy. 2014;9(9).
- 17. Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, Salahuddin N, et al. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. The International Journal of Tuberculosis and Lung Disease. 2011;15(11):1556–60. pmid:22008773
- 18. Gelmanova I Y K S, Golubchikova V T, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703–711. pmid:18026627
- 19. Jakubowiak W M B EM, Borisov E S, Danilova D I, Kourbatova E K. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007; 11: 46–53. pmid:17217129
- 20. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Annals of internal medicine. 2009;150(11):766–75. pmid:19487711
- 21. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Annals of internal medicine. 2006;144(9):650–9. pmid:16670134
- 22. Lee HY, Chae KO, Lee CH, Choi SM, Lee J, Park YS, et al. Culture conversion rate at 2 months of treatment according to diagnostic methods among patients with culture-positive pulmonary tuberculosis. PloS one. 2014;9(8):e103768. pmid:25105410
- 23. Putri FA, Burhan E, Nawas A, Soepandi P, Sutoyo D, Agustin H, et al. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. The International Journal of Tuberculosis and Lung Disease. 2014;18(5):564–70. pmid:24903794
- 24. Caetano Mota P C A, Valente I, Braga R, Duarte R. Predictors of delayed sputum smear and culture conversion among a Portuguese population with pulmonary tuberculosis. Rev Port Pneumol. 2012;18(2):72–9. pmid:22277838.
- 25. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117(3):744–51. pmid:10713001
- 26. Basit A, Ahmad N, Khan AH, Javaid A, Syed Sulaiman SA, Afridi AK, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PloS one. 2014;9(4):e93206. pmid:24705411
- 27. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. American journal of respiratory and critical care medicine. 2009;180(3):273–80. pmid:19406981
- 28. Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, et al. Chest radiograph findings and time to culture conversion in patients with multidrug-resistant tuberculosis and HIV in Tugela Ferry, South Africa. PloS one. 2013;8(9):e73975. pmid:24040132
- 29. Metlay JP K W, Fine MJ (1997). "Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination". JAMA: the Journal of the American Medical Association. 278 (17): 1440–5. pmid:9356004.